重组人4-1BB蛋白-ACROBiosystems百普赛斯

Biotinylated Human 4-1BB / TNFRSF9 Protein, His,Avitag™(MALS verified)

分子别名（Synonym）

TNFRSF9,4-1BB,CD137,CDw137,ILA

表达区间及表达系统（Source）

Biotinylated Human 4-1BB, His,Avitag (41B-H82E6) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # Q07011-1).

Predicted N-terminus: Leu 24

蛋白结构（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 20.9 kDa. The protein migrates as 30-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记（Labeling）

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度（Protein Ratio）

Passed as determined by the HABA assay / binding ELISA.

内毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method.

纯度（Purity）

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景（Background）

4-1BB也被称为CD137，肿瘤坏死因子受体超家族成员9（TNFRSF9），由淋巴细胞活化（ILA）诱导，是肿瘤坏死因子（TNF）受体超家族的共刺激分子。CD137可以由活化的T细胞表达，但在CD8上的表达程度大于CD4 T细胞。此外，在炎症部位的树突细胞、滤泡树突细胞、自然杀伤细胞、粒细胞和血管壁细胞上发现了CD137的表达。CD137的最佳特征活性是其对活化T细胞的共刺激活性。CD137的交联增强T细胞增殖、IL-2分泌存活和细胞溶解活性。此外，它可以增强免疫活性，消除小鼠的肿瘤。当TCR/CD3复合物结合时，CD137可以增强活化诱导的T细胞凋亡。此外，4-1BB/4-1BBL共刺激途径已被证明可以增强对几种病毒的次级CTL反应，同时增强抗肿瘤免疫。因此，4-1BB是人类癌症免疫治疗的一种有前景的候选物。CD137已被证明与TRAF2相互作用。